Viking Therapeutics, Inc. (VKTX) News
Track canonical SquawkNews coverage tagged to VKTX, Viking Therapeutics, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 9 indexed stories across 7 publication days and is ordered by the same first-publication timeline used by LiveCast.
H
VKTX Maintains Outperform
VKTX Q2 solidifies obesity strategy
EQUITY | Jul 30, 2026, 12:44 PM UTC
L
VKTX Viking Therapeutics RESULTS: Q2, Q2 EPS $-1.1 vs. EST $-1.25, Q2 Income from operations $-132.597M vs. EST $-150.3M, Q2 Net Income $-12
VKTX Viking Therapeutics RESULTS: Q2, Q2 EPS $-1.1 vs. EST $-1.25, Q2 Income from operations $-132.597M vs. EST $-150.3M, Q2 Net Income $-128.022M vs. EST $-144.7M, Q2 operating expenses $132.597M
EARNINGS | Jul 29, 2026, 08:09 PM UTC
L
VKTX - Viking Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
VKTX - Viking Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
EARNINGS | Jul 29, 2026, 08:06 PM UTC
L
VKTX Reiterate Buy with PT $95 as upcoming maintenance readout could guide Ph.3 Extensions and enhance VK2735 Commercial competitiveness @ S
VKTX Reiterate Buy with PT $95 as upcoming maintenance readout could guide Ph.3 Extensions and enhance VK2735 Commercial competitiveness @ Stifel
EQUITY | Jul 24, 2026, 11:24 AM UTC
L
VKTX Maintain Buy and $107 PT as Preview VK2735 maintenance study data read-out @ Canaccord
VKTX Maintain Buy and $107 PT as Preview VK2735 maintenance study data read-out @ Canaccord
EQUITY | Jul 15, 2026, 01:03 PM UTC
L
How Much Could $1,000 Invested in Viking Therapeutics Be Worth by 2030?
2026-07-05 01:25:00 ET Viking Therapeutics (NASDAQ: VKTX) is a challenger in the obesity drugs go
EQUITY | Jul 05, 2026, 05:26 AM UTC
L
Here's Why Viking Therapeutics Stock Surged Higher in June
2026-07-03 09:45:39 ET Viking Therapeutics (NASDAQ: VKTX) stock rose by 19.2% in
EQUITY | Jul 03, 2026, 01:46 PM UTC
M
VKTX Advances Weight-Loss Drug
Viking Therapeutics initiates Phase 1 trial for VK3019, a dual amylin and calcitonin receptor agonist for weight loss
EQUITY | Jun 24, 2026, 01:05 PM UTC
L
VKTX Initiates Phase 1 Study
Viking Therapeutics initiates Phase 1 study to evaluate novel amylin receptor agonist VK3019 in healthy adults
EQUITY | Jun 24, 2026, 11:05 AM UTC